Actively Recruiting
Phase 1 Trial Evaluating the Effects of Multiple Doses of Itraconazole on Nacresertib in Healthy Adults Aged 18 to 65
Led by AbbVie · Updated on 2026-07-23
12
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating how multiple doses of Itraconazole affect the performance of Nacresertib in healthy adult volunteers aged 18 to 65. The purpose is to assess the safety and drug interaction between these two medications. This Phase 1 study is designed to understand how Itraconazole impacts the behavior of Nacresertib in the body. Participants will receive a single dose of Nacresertib on Day 1 in the first period. In the second period, they will take multiple doses of Itraconazole starting on Day 1, followed by daily single doses from Days 2 through 11, along with a single oral dose of Nacresertib on Day 4. The study uses a crossover design to compare the effects of Nacresertib alone and in combination with Itraconazole. Throughout the study, participants will attend regular weekly and monthly visits at a hospital or clinic. Researchers will conduct medical assessments, blood tests, monitor side effects, and collect questionnaire responses to check the treatment effects. Key measurements include various plasma concentration levels and elimination rates of Nacresertib up to Day 12, ensuring close safety monitoring and detailed drug interaction evaluation.
CONDITIONS
Brief Title
A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
